Dr James Wilmott awarded for outstanding cancer research
6 August 2016
Research Associate at Melanoma Institute Australia, Dr James Wilmott, was awarded the Wildfire Award at last night's Cancer Institute NSW's Premier Awards for Outstanding Cancer Research.
The 'Wildfire' Highly Cited Publication Award is given to a NSW researcher who has made a significant difference to cancer research, care or practice through authoring a highly cited publication that is expected to significantly influence cancer control or further research.
His publication ‘Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma external’ is being used by pathology departments around the world to triage patients into lifesaving personalised medicines.
Some patients only have days to live without intervention and cannot wait for routine molecular testing results.
The assay described in the publication allows patients who could die waiting to be tested and treated with lifesaving drugs.
Dr Wilmott has authored more than 50 manuscripts which have been cited over 1400 times. His research interests are biomarker studies of patients treated with targeted therapies and he is currently working as the Project Manager for the Australian Melanoma Genome Project.
As part of the prestigious award, Dr Wilmott will be granted $20,000 to future research endeavours.
Previous winners of the Wildfire Award from MIA include Prof Georgina Long (in 2014) and A/Prof Pascale Guitera (in 2013).
"International collaboration remains the key to ensuring this pioneering research continues so we can increase survival rates for advanced melanoma patients and move us closer to achieving our goal of zero deaths from melanoma," says Professor Georgina Long, of the clinical trial results presented at ESMO 2018.
Research that could change clinical practice for high-risk Stage III melanoma patients has been presented at the European Society for Medical Oncology (ESMO) Congress in Munich.
A larger, monthly dose of immunotherapy can give melanoma patients more freedom without sacrificing effectiveness.
The Australasian Melanoma Conference, hosted by the Australasian Melanoma Conference Committee, was held in Melbourne on the weekend, with many of MIA's clinicians in attendance.
The two men who discovered checkpoint inhibitors, the brakes of the immune system, were awarded the Nobel Prize in Physiology or Medicine on Monday, October 1.
The World Health Organisation (WHO) is releasing the 4th edition of Classification of Skin Tumours.
Former Executive Director of Melanoma Institute Australia Professor John Thompson awarded the prestigious 2018 RPA Foundation Research Medal.
Clinicians, patients and other stakeholders in the cancer community are invited to make submissions in support of the PBS listing for pembrolizumab.
The World Congress on Cancers of the Skin 2018 has featured many minds from MIA sharing their expertise and wealth of knowledge with over 1000 attendees from around the world.
Melanoma Institute Australia is delighted to announce the appointment of Matthew Browne as Chief Executive Officer (CEO).
It was a full house this week at Melanoma Institute Australia thanks to our ‘Melanoma in Practice: Nurse Conference’.
A new study from The University of Sydney shows that sunscreen reduces melanoma risk by 40 per cent when used from a young age.
Melanoma Institute Australia (MIA) has launched a free e-learning portal to educate healthcare professionals about the latest advances in melanoma diagnosis and treatment.
When David lost his life last year, he was 33, with three daughters under six.
Clinical trials are just that – trials in a clinical setting to evaluate the effectiveness or otherwise of individual and combination treatments.
Melanoma Institute Australia scooped the award pool at the Annual Scientific Meeting of the International Academy of Pathology.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.